FOR IMMEDIATE RELEASE
September 28, 2022

Media Contact:
Amanda McGee
Director of Marketing & Communications
Communication@LissMD.com
(706) 327-4000

Eisai Co., Ltd. and Biogen Inc. have announced that Lecanemab has demonstrated a significant reduction of clinical decline in early Alzheimer’s disease. Lecanemab is likely to be the first fully approved disease modifying drug for this dreaded illness. Columbus, Georgia, home to Columbus Memory Center, has less than 200,000 people, but enrolled the third highest number of research subjects for each of Lecanemab’s pivotal trials

COLUMBUS, GA. Sept 28, 2022 – Columbus Memory Center is proud to share exciting news in the fight against Alzheimer’s Disease. Clarity AD, the clinical trial of the investigational drug Lecanemab, has produced positive topline results during it’s Phase 3 trial period. The treatment reduced clinical decline on the global cognitive and functional scale, CDR-SB, compared to placebo at 18 months by 27%. Statistical changes occurred in as few as 6 months compared to placebo.

“…The successful results of the Clarity AD clinical trial would not be possible without the truly inspiring dedication of the study’s participants, their families and caregivers and the clinical investigators around the world. We thank all the people involved in the study for their invaluable contributions,” noted Eisai Chief Executive Officer, Naruo Naito

“Huge news! We did it! Lecanemab will be the first fully proven monoclonal antibody for Alzheimer’s disease and will likely be classified as the first ever disease modifying agent for Alzheimer’s disease.” said Neurologist, Dr. Jonathan Liss, President of Columbus Memory Center and Site Principal Investigator for Clarity AD. “Once untreatable, this is now a disease that enters into the world of sub-specialist focus. CMC had the third highest enrollment in the world for both pivotal trials. We are proud to be recognized as a world leader!

About Columbus Memory Center

Columbus Memory Center is a world leader in Alzheimer’s clinical care and research. The center is credited for its commitment to ending Alzheimer’s in this generation through initiatives such as the Columbus Memory Project and the creation of the world’s first vital sign for brain health, the Memory Number®. For more information about Columbus Memory Center, visit www.columbusmemorycenter.com.

More information about Lecanemab, Biogen and Eisai can be found in their press release available here.